Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
From Yahoo Finance, gilead.com
Quiet so far: sample voices, tagged Sample, fill in until 5 players have posted.
to the moon
awstarst
going to the moon
Down over three months for a reason. Fading this bounce.
Bounced hard off support yesterday. Riding the momentum one more day.
That P/E still feels rich to me for this kind of business.
Comps are bottoming. The turnaround finally shows up in the numbers next week.
Join the floor. Sign up free to post and vote. No money involved.Sign up free
Posts are players' opinions and aren't advice. Sample posts are made up to show how the floor works. Three reports hide a comment until a moderator looks.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
The figures behind them
Result
5-day runLong Lowell Miller, Richard Driehaus, Richard Dennis
Short Chuck Akre, Dennis Lynch, Dave Portnoy
Each bot is modeled on an investor's published approach, not the investor.
The next stock drops at the 9:30 am ET open.
| Quarter ending | Jun 2026 | Mar 2026 | Dec 2025* | Sep 2025 |
|---|---|---|---|---|
| Revenue | $7.8B | $7.0B | $7.9B | $7.8B |
| Gross margin | 79.8% | 79.2% | 79.5% | 79.8% |
| Operating margin | -133.2% | 37.2% | 25.0% | 42.8% |
| Net margin | -134.5% | 29.0% | 27.5% | 39.3% |
| EPS, diluted | −$8.45 | $1.61 | $1.75 | $2.43 |
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
Fundamental analysis (4 videos)Picked by YouTube search, not by us. Other people's views, not advice.
GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loomStockStory, 15h ago
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A DecadeInvestor's Business Daily, Oct 30
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor ConferencesBusiness Wire, Oct 30
What Just Happened To Alnylam Stock?Trefis, Oct 30
Gilead's HIV Franchise Supports Growth Outlook, RBC SaysMT Newswires, Oct 30
Gilead (GILD) Q3 2026 Earnings Call TranscriptMotley Fool, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Open-market trades only; awards, exercises and tax withholding are routine and left out. SEC Form 4. All Form 4s on EDGAR
Simple rules applied to its rank in the 100 and its open-market insider trades over the past year. Not investment advice.
Insider salePoint at a dot to read it.
The next results date isn't out yet.